- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04123444
Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure (COMBAT-SHINE)
Efficacy and Safety of 72-hour Infusion of Prostacyclin (1 Nanogram(ng)/Kilo(kg)/Minute(Min)) in Patients With Septic Shock Induced Endotheliopathy - a Multicentre Randomized, Placebo-controlled, Blinded, Investigator-initiated Trial"
The purpose of this trial is to investigate the efficacy and safety of continuous intravenous administration of low dose iloprost versus placebo for 72-hours, in up to a total of 380 patients with septic shock suffering from organ failure.
The study hypothesis is that iloprost may be beneficial as an endothelial rescue treatment as it is anticipated to deactivate the endothelium and restore vascular integrity in septic shock patients suffering from organ failure caused by endothelial breakdown, ultimately improving survival.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with the most severe type of sepsis, those with septic shock have a mortality rate between 30% to 45% due to multiple organ failure. The poor outcome of shocked patients, and especially those with sepsis, may by related to microvascular endothelial dysfunction. Evidence support that iloprost infusion significantly improved endothelial function and integrity,
The main objective in this trial is to investigate whether continuous infusion of lov dose iloprost at a dose of 1 ng/kg/min for 72-hours is safe and significantly reduce organ failure score in the intensive care unit (ICU) compared to infusion of placebo in patients with septic shock induced endotheliopathy (SHINE).
Patients that are eligible for this trial will be temporarily incompetent due to acute severe illness relating to septic shock, therefore informed consent will be obtained from a scientific guardian. Next-of kin and subsequently the patient will co-sign as soon as possible hereafter. During the trial, patient will be give continuous infusion of low dose iloprost or placebo for 72 hours as well as additional blood samples will be obtained daily for the first 72 hours. Follow up on organ failure, mortality and quality of life will be performed on dag 28 and 90.
This trial is conducted in accordance with the Helsinki 2 Declaration and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Guideline for Good Clinical Practice (ICH-GCP) and in compliance with the protocol. As part of the quality assurance on-site monitoring visit will be performed by the an independent GCP-unit including source data verification. Standard Operation Procedure (SOP) to address protocol specific procedures such as data collection and adverse event reporting are developed.
The number of patients participating is based on a power calculation using the data on mean daily SOFA score from a recent randomized, double blind, placebo controlled clinical trial in patients with septic shock: Levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARD). If the true effect of the intervention is a reduction in mean daily SOFA score of 20% (relative) and providing the trial with 90% power to detect this difference at a significance level of 0.05 will require a sample size of 380 patients.
A pre-planned, blinded interim analysis will be performed after 200 patients have been included in the trial and followed for 90 days.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Jakob Stensballe, MD, PhD
- Phone Number: +45 3545 8587
- Email: jakob.stensballe@regionh.dk
Study Contact Backup
- Name: Pär I Johansson, MD, MPA
- Phone Number: +45 3545 2032
- Email: per.johansson@regionh.dk
Study Locations
-
-
-
Copenhagen, Denmark
- Dept. of Anaesthesia and Intensive Care, Bispebjerg Hospital
-
Copenhagen, Denmark
- Dept. of Intensive Care, Copenhagen University Hospital, Rigshospitalet
-
Herlev, Denmark
- Dept. of Intensive Care, Copenhagen University Hospital Herlev
-
Hillerød, Denmark
- Dept. of Anaesthesia and Intensive Care, Nordsjaelands Hospital
-
Hvidovre, Denmark
- Dept. of Anaesthesia and Intensive Care, Hvidovre Hospital
-
Køge, Denmark
- Region Sealand University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All the following criteria must be fulfilled:
- Adult intensive care patients (age ≥ 18 years)
Septic shock defined according to the Sepsis-3 criteria:
- suspected or documented infection
- persisting hypotension requiring vasopressors to maintain a mean arterial blood pressure of 65 mmHg or above
- Lactate level of 2 mmol/L or above despite fluid therapy within the last 3 hours at screening
- Soluble thrombomodulin (sTM) above 10 ng/mL
Exclusion Criteria:
Patients who fulfil any of the following criteria will be excluded:
- Withdrawal from active therapy
- Pregnancy
- Known hypersensitivity to iloprost.
- Life-threatening bleeding as defined by the treating physician
- Known severe heart failure (New York Heart Association (NYHA) class IV)
- Suspected acute coronary syndrome
- Previously included in this trial
- Septic shock for more than 12 hours at the time of screening
- Informed consent cannot be obtained
- Included in other clinical trials with prostacyclin within 90 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Iloprost
Patients randomized to active treatment (n=190 patients) will receive continuous infusion of iloprost for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
|
Continuously infusion for 72 hours.
treatment dose 1 ng/kg/min
Other Names:
|
Placebo Comparator: Placebo
Patients randomized to placebo treatment (n=190 patients) will receive continuous infusion of placebo for 72 hours after inclusion or until discharge to ward or death, whichever comes first.
|
Continuously infusion for 72 hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modified Sequential Organ Failure Assessment (SOFA)
Time Frame: Up to 90 days after randomization
|
Mean daily modified SOFA score in the intensive care unit (scores for each of five systems range from 0 to 4, with higher scores indicating more severe dysfunction; range score 0-20).
|
Up to 90 days after randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
28 and 90-day mortality
Time Frame: Day 28 and 90 after randomization
|
Vital status of the patient at day 28 and day 90
|
Day 28 and 90 after randomization
|
Vasopressor free days
Time Frame: Until ICU discharge, maximun 90 days after randomization
|
Days alive and without vasopressor at day 90.
|
Until ICU discharge, maximun 90 days after randomization
|
Mechanical ventilation free days
Time Frame: Until ICU discharge, maximun 90 days after randomization
|
Days alive and without invasive mechanical ventilation at day 90
|
Until ICU discharge, maximun 90 days after randomization
|
Renal replacement free days
Time Frame: Until ICU discharge, maximun 90 days after randomization
|
Days alive and without renal replacement therapy at day 90
|
Until ICU discharge, maximun 90 days after randomization
|
Serious adverse reactions (SARs)
Time Frame: Until day 7 after randomization
|
Numbers of patients with one or more serious adverse reactions (SARs) and total number of SARs
|
Until day 7 after randomization
|
Serious adverse events (SAEs)
Time Frame: Until day 7 after randomization
|
Numbers of patients with one or more and total number of serious adverse events and total number of SAEs; SAEs defined as ischaemic events and bleeding events (requiring more than 2 red blood cells (RBCs) within 24 hours or ongoing bleeding.
|
Until day 7 after randomization
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Morten Bestle, MD, PhD, Nordsjaelands Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- COMBAT-SHINE
- 2019-001131-31 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septic Shock
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityUnknown
-
University of ZurichCompletedPatients in Septic ShockSwitzerland
Clinical Trials on Iloprost
-
University of OklahomaCompletedChronic Obstructive Pulmonary Disease | Pulmonary HypertensionUnited States
-
Charite University, Berlin, GermanySchering-PloughTerminatedSystemic SclerosisGermany
-
ActelionTerminatedPulmonary Arterial HypertensionUnited States
-
ActelionTerminatedPulmonary HypertensionUnited States
-
Loma Linda UniversityWithdrawnHypoxic Pulmonary VasoconstrictionUnited States
-
National Center for Research Resources (NCRR)University of PittsburghCompletedSystemic Sclerosis | Raynaud Disease
-
Lund University HospitalBayerWithdrawnRespiratory Distress Syndrome | Persistent Pulmonary HypertensionSweden
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedLung Cancer | Precancerous ConditionUnited States
-
BayerCompletedHypertension, PulmonaryItaly, Spain, France, Germany, Portugal, United Kingdom
-
University of ChicagoTerminatedPulmonary HypertensionIsrael, United States